← Leaderboards
Timothy M Fan
University Of Illinois At Urbana-Champaign
$2,335,730
Attributed
$6,135,401
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,135,401 · 3
By mechanism
R01$6,135,401 · 3
Top collaborators
- David R Andes5 shared
- Martin D Burke5 shared
- William J Steinbach5 shared
- Karl D Wittrup4 shared
Most similar at University Of Illinois At Urbana-Champaign
Same institution · by research overlap
- Jianjun Cheng$6,510,347
- Martin D Burke$12,631,399
- Stephen Moose$5,037,492
- Jianjun Cheng$2,018,334
Others in their field
Other Emerging Leaders on “Safety”
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
- Kimberly Smith · Ppd Development Lp$122,008,792
- Klaus Romero · Critical Path Institute$90,404,592
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$75,904,237
- Yunda Huang · Fred Hutchinson Cancer Center$70,809,823
- Leonard Freedman · Leidos Biomedical Research, Inc.$64,938,611
Research focus
SafetyMouse ModelDesignAnimalsTreatment ProtocolsExhibitsMonitorDoseBindingCellsProgramsPharmacodynamicsTherapeutic IndexCanis FamiliarisBaseClinicPharmaceutical PreparationsLifeIn VitroFormulationIn VivoMolecularEfficacy StudyChronic
Grant awards (10)
Intratumoral Cytokine Immunotherapy Studies in Companion Canine Cancer Models$511,429
R01 · FY2025 · CA
Intratumoral Cytokine Immunotherapy Studies in Companion Canine Cancer Models$484,753
R01 · FY2024 · CA
Intratumoral Cytokine Immunotherapy Studies in Companion Canine Cancer Models$498,957
R01 · FY2023 · CA
Development of non-toxic amphotericin B derivatives targeting invasive fungal infections$702,349
R01 · FY2022 · AI
Intratumoral Cytokine Immunotherapy Studies in Companion Canine Cancer Models$521,821
R01 · FY2022 · CA
Development of non-toxic amphotericin B derivatives targeting invasive fungal infections$714,404
R01 · FY2021 · AI
Precision nanotherapeutics for cancer treatment$396,853
R01 · FY2021 · CA · contact PI
Development of non-toxic amphotericin B derivatives targeting invasive fungal infections$745,652
R01 · FY2020 · AI
Development of non-toxic amphotericin B derivatives targeting invasive fungal infections$757,553
R01 · FY2019 · AI
Development of non-toxic amphotericin B derivatives targeting invasive fungal infections$801,630
R01 · FY2018 · AI